Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="10"><hr/></td></tr><tr class="thead"><td class="align_left" rowspan="2">Complex</td><td class="align_center" colspan="9">Percentage of protein secondary structure</td></tr><tr class="thead"><td class="align_center">Structure</td><td class="align_center">Coil</td><td class="align_center"><i>β</i>-Sheet</td><td class="align_center"><i>β</i>-Bridge</td><td class="align_center">Bend</td><td class="align_center">Turn</td><td class="align_center"><i>α</i>-Helix</td><td class="align_center">5-Helix</td><td class="align_center">3-Helix</td></tr><tr><td class="thead-hr" colspan="10"><hr/></td></tr><tr><td class="align_left">TGF-<i>β</i>1</td><td class="align_center">0.62</td><td class="align_center">0.24</td><td class="align_center">0.35</td><td class="align_center">0.03</td><td class="align_center">0.12</td><td class="align_center">0.08</td><td class="align_center">0.16</td><td class="align_center">0.02</td><td class="align_center">0.00</td></tr><tr><td class="align_left">TGF-<i>β</i>1-silmitasertib</td><td class="align_center">0.67</td><td class="align_center">0.21</td><td class="align_center">0.41</td><td class="align_center">0.02</td><td class="align_center">0.10</td><td class="align_center">0.10</td><td class="align_center">0.15</td><td class="align_center">0.01</td><td class="align_center">0.00</td></tr><tr class="table-tr"><td colspan="10"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Percentage of residues participated in average structure formation.</div>

BioMed Research International

tab4

Table 4

Table 4: Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis 

Table 4 | Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis 